Celltrion to study efficacy of Remsima on COVID-19 in Britain
SEOUL, June 10 (Yonhap) -- An affiliate of South Korean biopharmaceutical firm Celltrion Inc. said Wednesday that it will begin a study on the treatment efficacy of its biosimilar Remsima on the novel coronavirus.
Celltrion Healthcare, which handles Celltrion's overseas business, said the trial study of Remsima, a biosimilar drug to treat autoimmune diseases, will be conducted in Britain this month.
The study will be conducted in collaboration with Marc Feldmann, an immunologist at the University of Oxford, it said.
In April, Feldmann said anti-tumor necrosis factor (TNF) inhibitor should be used to treat COVID-19 patients, as antibodies have been used for more than 20 years in severe cases of autoimmune inflammatory disease, such as rheumatoid arthritis.
"We propose that anti-TNF therapy should be evaluated in patients with COVID-19 on hospital admission to prevent progression to needing intensive care support," according to his research paper released in the medical journal Lancet.
Remsima, also a TNF inhibitor, is referecing Janssen Biotech Inc.'s Remicade and is effective in treating various autoimmune diseases, from rheumatoid arthritis to Crohn's disease.
Remsima was Celltrion's second biosimilar approved by the U.S. Food and Drug Administration. Biosimilars are officially approved copycat medicines developed after patents for the original drugs expire.
khj@yna.co.kr
(END)
-
Ateez to drop new Japanese EP next week
-
Gov't to significantly increase international flights to meet travel demand
-
(2nd LD) BTS wins three Billboard Music Awards, marking 6th year to win an award
-
Crypto investor probed over allegedly visiting house of Terraform's CEO
-
(2nd LD) N. Korea still unresponsive to S. Korea's outreach for talks on COVID-19: official
-
S. Korea to send condolence delegation to UAE over death of president
-
(LEAD) N. Korea confirms first case of omicron variant of COVID-19: state media
-
Seoul's daily subway ridership hits pandemic-era high on eased restrictions
-
(5th LD) N.K. leader, wearing mask, chairs meeting on omicron outbreak
-
(URGENT) N. Korea says fever symptoms reported among more than 18,000 people Thursday alone amid COVID-19 outbreak
-
(LEAD) S. Korea looks into cryptocurrency market following TerraUSD, Luna crash
-
U.S. Forces Korea launches permanent Apache helicopter unit
-
S. Korea's new COVID-19 cases above 30,000 for 2nd day amid omicron slowdown
-
Yoon, PPP lawmakers travel to Gwangju en masse to commemorate 1980 democracy uprising
-
U.S. concerned about COVID outbreak in N. Korea, no delay in nuclear test expected: State Dept.